Cadila Pharma launches generic sitagliptin versions to treat uncontrolled type 2 diabetes
01 August 2022 | News
The two generic drugs have been launched under the brand names Jankey and Sitenali
Ahmedabad-based Cadila Pharmaceuticals has launched the generic versions of sitagliptin in India under the brand names Jankey and Sitenali to address type 2 diabetes.
Sitagliptin is a drug from the class of DPP-4 inhibitors, and a one-of-its-kind drug for the treatment of high glucose levels in the blood, also known as hyperglycaemia.
High blood glucose can lead to life-threatening complications such as atherosclerosis, stroke, heart attack, retinopathy, neuropathy and nephropathy.
The company has also launched a potent combination of Sitagliptin and Metformin and branded it as Jankey M.
Sitagliptin has a strong clinical profile and the potential to revolutionise the treatment of type 2 diabetes for millions of people who do not achieve the targeted blood sugar level with currently available anti-diabetic medications.
